Increasing awareness and knowledge of Alpha-gal Syndrome in the United States
Closed Posted
- Opportunity number
- CDC-RFA-CK-26-0193
- Agency
-
Centers for Disease Control and Prevention
Department of Health and Human Services
- Applications due
- Award size
- $25,000 to $1,000,000
Opportunity facts
- Assistance listings
- Funding instrument
- Cooperative Agreement
- Category
-
- Health
- Eligible applicants
-
- County Governments
- Public or Indian Housing Auth.
- 501(c)(3) Nonprofits
- Independent School Districts
- City/Township Governments
- Tribal Organizations (Not Federally Recognized)
- Higher Education Inst. (Private)
- Non-501(c)(3) Nonprofits
- Unrestricted
- State Governments
- Higher Education Inst. (Public)
- For Profit Organizations
- Small Businesses
- Special District Governments
- Tribal Governments (Federally Recognized)
- Points of contact
-
- Jeff Borchert gqx1@cdc.gov (970) 221-6494
Opportunity details come from Grants.gov. Updated .
About this opportunity
The Centers for Disease Control and Prevention (CDC) is soliciting applications for cooperative agreements to increase awareness and knowledge of alpha-gal syndrome (AGS) in the United States, with applications due July 9, 2026. All applicant types are eligible, including state and local governments, tribal entities, institutions of higher education, nonprofits (including faith-based organizations), for-profit organizations, and small businesses. No cost share is required. The CDC expects to make 1 to 5 awards totaling $25,000,000 over five years, with individual awards ranging from $25,000 to $1,000,000 per year; applicants should estimate an average annual funding level of $400,000 per year for planning purposes.
Applicants must propose the SHARE strategy—formation of a network of AGS professionals to disseminate knowledge among public health agencies, academic researchers, and advocacy groups—and may optionally propose the EDUCATE strategy (create targeted communications for the general public, AGS patients, healthcare providers, and high-risk populations such as outdoor enthusiasts and dog owners) and the TRACK strategy (conduct active or enhanced surveillance for AGS in underserved geographic areas and at-risk populations, considering Social Determinants of Health impacts).
The expected award date is August 31, 2026, with a project start date of September 30, 2026. The project period is five years with 12-month budget periods. Merit review assesses background and approach (60 points), evaluation and performance measurement plan (20 points), and organizational capacity (20 points, 100 points total). Applications must include a 20-page project narrative, budget narrative, evaluation and performance measurement plan, data management plan, organizational capacity documentation, organizational chart, resumes of key personnel, and letters of support (maximum 5). All applications are submitted through Grants.gov and subject to responsiveness screening and risk assessment. Recipients must maintain active SAM.gov registration with a Unique Entity Identifier and commit to quarterly or more frequent performance reporting, including financial reports and evaluation data. The funding instrument is identified under CFDA 93.084 (Prevention of Disease, Disability, and Death by Infectious Diseases).
Synopsis
2 versions
Update #2 · Latest ·
The purpose of this NOFO is to improved awareness and knowledge of alpha-gal syndrome (AGS) in the United States. AGS is an emerging condition and is not nationally notifiable. This NOFO seeks to improve AGS surveillance, patient care, and public awareness and understanding. The NOFO strategies are to 1) SHARE - Formation of a network of AGS professionals to disseminate latest knowledge of AGS among stakeholders, including public health agencies, academic researchers, and advocacy groups, in order to improve patient care for AGS and the public health response. 2) EDUCATE - Create AGS communications targeted at the general public, AGS patients, or persons at higher risk for tick encounters (outdoor enthusiasts, dog owners, outdoor workers, etc.). Create communications targeted at healthcare providers including educational resources and training. 3) TRACK - Conduct active or enhances public health surveillance for AGS. This strategy could involve patient populations or geographical locations with limited access to specialized healthcare provider care.
Update #1 ·
The purpose of this NOFO is to improved awareness and knowledge of alpha-gal syndrome (AGS) in the United States. AGS is an emerging condition and is not nationally notifiable. This NOFO seeks to improve AGS surveillance, patient care, and public awareness and understanding. The NOFO strategies are to 1) SHARE - Formation of an association of AGS professionals to disseminate latest knowledge of AGS among stakeholders, including public health agencies, academic researchers, and advocacy groups, in order to improve patient care for AGS and the public health response. 2) EDUCATE - Create AGS communications targeted at the general public, AGS patients, or persons at higher risk for tick encounters (outdoor enthusiasts, dog owners, outdoor workers, etc.). Create communications targeted at healthcare providers including educational resources and training. 3) TRACK - Conduct active or enhances public health surveillance for AGS. This strategy could involve patient populations or geographical locations with limited access to specialized healthcare provider care. Social Determinants of Health impacts could be considered as well. Please note that applicants must apply for strategy number 1 (SHARE) and that strategies 2 (EDUCATE) and 3 (TRACK) are optional.
Files
| File | Type | Posted |
|---|---|---|
| ck-26-0193_forPublication_Mod1.pdf | ||
| ck-26-0193_forPublication.pdf |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar grant opportunities
- Ask GovTribe AI about this opportunity